Ralph Tripp

Animal Health Research Center
Center for Vaccines and Immunology
Department of Infectious Diseases
CVI Affiliated Faculty
Georgia Research Alliance Chair of Animal Health Vaccine Development
GRA Eminent Scholar
Email Me
– OR –
p: 706.542.1557


  • Immunology
  • Immunology and Infectious Disease
  • Infectious Diseases
  • Vaccinology
  • Virology


Dr. Ralph Tripp is a Professor in the Department of Infectious Diseases in the College of Veterinary Medicine and is a Georgia Research Alliance Eminent Scholar.  Dr. Tripp was trained in the field of viral immunity with Laureate Professor Peter C. Doherty at St. Jude Children’s Research Hospital and, prior to joining UGA in 2004, led a research team in respiratory virus immunology studies at the Centers for Disease Control and Prevention in Atlanta, GA.  His primary research interest is to develop translational disease intervention strategies for emerging respiratory viruses. Dr. Tripp’s laboratory investigates the mechanisms of immunity and disease pathogenesis associated with respiratory virus infection to better understand the conceptual and functional differences between innate and adaptive immune responses that provide the foundation necessary to facilitate vaccine and antiviral therapeutic protocols. They also investigate the host cell and viral regulatory pathways involving small RNAs, such as microRNAs.  Dr. Tripp holds adjunct Professorships in the Centre for Molecular Sciences at University Canberra, AUS, the School of Infection & Host Defense at the University of Liverpool, UK, and in the Centre for Molecular & Medical Research at Deakin University, AUS.

Research Interests

Research interests include understanding the mechanisms of immunity and disease pathogenesis associated with respiratory virus infection, and using this information to develop therapeutic protocols and vaccines that will confer long-term protective immunity.

Educational Background

​PhD (1989) Oregon State University

Selected Publications

My Bibliograpy – NCBI

Search PubMed for “tripp ra”

  • Caidi H, Harcourt JL, Tripp RA, Anderson LJ, Haynes LM. Combination Therapy Using Monoclonal Antibodies against Respiratory Syncytial Virus (RSV) G Glycoprotein Protects from RSV Disease in BALB/c Mice. PLoS One.  2012; 7(12):e51485.
  • Laing EM, Tripp RA, Pollock NK, Baile CA, Della-Fera MA, Rayalam S, Tompkins SM, Keys DA, Lewis RD. Adenovirus 36, adiposity, and bone strength in late-adolescent females. J Bone Miner Res. 2013 Mar; 28(3): 489-96.
  • Perwitasari O, Yan X, Johnson S, White C, Brooks P, Tompkins SM, Tripp RA. Targeting organic anion transporter 3 with probenecid as a novel anti-influenza a virus strategy. Antimicrob Agents Chemother. 2013 Jan; 57(1): 475-83
  • Bakre A, Mitchell P, Coleman JK, Jones LP, Saavedra G, Teng M, Tompkins SM, Tripp RA. Respiratory syncytial virus modifies microRNAs regulating host genes that affect virus replication. J Gen Virol. 2012 Nov; 93(Pt 11): 2346-56.
  • Abell JL, Garren JM, Driskell JD, Tripp RA, Zhao Y. Label-Free Detection of Micro-RNA Hybridization Using Surface-Enhanced Raman Spectroscopy and Least-Squares Analysis. J Am Chem Soc. 2012 Jul 19
  • Meliopoulos VA, Andersen LE, Brooks P, Yan X, Bakre A, Coleman JK, Tompkins SM, Tripp RA. MicroRNA regulation of human protease genes essential for influenza virus replication. PLoS One. 2012; 7(5):e37169.
  • Choi Y, Mason CS, Jones LP, Crabtree J, Jorquera PA, Tripp RA. Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains. Viral Immunol. 2012 Jun; 25(3):193-203
  • Singh JP, Chu H, Abell J, Tripp RA, Zhao Y. Flexible and mechanical strain resistant large area SERS active substrates. Nanoscale. 2012 Jun 7; 4(11):3410-4.
  • Meliopoulos VA, Andersen LE, Birrer KF, Simpson KJ, Lowenthal JW, Bean AG, Stambas J, Stewart CR, Tompkins SM, van Beusechem VW, Fraser I, Mhlanga M, Barichievy S, Smith Q, Leake D, Karpilow J, Buck A, Jona G, Tripp RA. Host gene targets for novel influenza therapies elucidated by high-throughput RNA interference screens. FASEB J. 2012 Apr; 26(4):1372-86
  • Gordy JT, Jones CA, Rue J, Crawford PC, Levy JK, Stallknecht DE, Tripp RA, Tompkins SM. Surveillance of feral cats for influenza A virus in north central Florida. Influenza Other Respi Viruses. 2012 Sep; 6(5):341-7.